-

06:37:58 AM

ZTS Stock News

ZTS - Zoetis Inc

01/13/22 1:36 PM

NYSE : ZTS

fda approval

Zoetis Announces FDA Approval of Solensia™ (frunevetmab injection) to Control Osteoarthritis Pain in Cats

Zoetis Inc. today announced that the U.S. Food and Drug Administration has approved Solensia™ to control the pain of osteoarthritis in cats, helping improve their mobility, comfort and overall well-being. 1 As a once-monthly injection administered in the veterinary clinic, Solensia keeps OA pain from disrupting the unique bond cats share with their humans.

RHEA-AI

neutral

01/06/22 8:00 AM

NYSE : ZTS

Zoetis Announces Expanded Commitments to Protect the Planet

Zoetis Inc., the world’ s leading animal health company, has refreshed its Driven to Care sustainability aspirations for mitigating the company’ s climate impact and environmental effects on the planet. As another step in its sustainability journey, the company’ s diagnostics site in San Diego is operating on 100% renewable electricity, which means 9 of the...

RHEA-AI

very positive

12/23/21 8:30 AM

NYSE : ZTS

conferences

Zoetis to Participate in the 40th Annual J.P. Morgan Healthcare Conference

Zoetis Inc. will participate in the 40 th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 10, 2022. Kristin Peck, Chief Executive Officer, will represent the company and respond to questions from analysts. She is scheduled to present at 1:30 p.m. ET.

RHEA-AI

neutral

12/23/21 8:00 AM

NYSE : ZTS

conferencesearnings

Zoetis to Host Webcast and Conference Call on Fourth Quarter and Full Year 2021 Financial Results

Zoetis Inc. will host a webcast and conference call at 8:30 a.m. on Tuesday, Feb. 15, 2022. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review fourth quarter and full year 2021 financial results and respond to questions from financial analysts during the call. A Fortune 500 company, Zoetis...

RHEA-AI

neutral

12/07/21 4:25 PM

NYSE : ZTS

buyback

Zoetis Announces Authorization of $3.5 Billion Share Repurchase Program

Zoetis Inc. today announced that its Board of Directors has approved a $3.5 billion share repurchase program as part of its capital allocation plans. The Company’ s previous $2.0 billion share repurchase program, which was approved in December 2018, is expected to be completed in 2022.. The dividend will be paid on Tuesday, March 1, 2022, to all holders of record of...

RHEA-AI

neutral

12/02/21 12:50 PM

NYSE : ZTS

Zoetis Named One of Newsweek’s Most Responsible Companies for 2022

Zoetis has been named to Newsweek Magazine's America's Most Responsible Companies 2022 list, which recognizes top-performing companies that are making a difference through their environmental, social and corporate governance actions. “Being recognized by Newsweek Magazine is a proud moment for Zoetis and affirms the way we strive to nurture the world...

RHEA-AI

very positive

11/04/21 7:00 AM

NYSE : ZTS

Zoetis Announces Third Quarter 2021 Results

Zoetis Inc. today reported its financial results for the third quarter of 2021 and increased its guidance for full year 2021.. Net income for the third quarter of 2021 was $552 million, or $1.16 per diluted share, an increase of 15% and 16%, respectively, on a reported basis. “We delivered strong results again this quarter with 10% operational growth for both revenue...

RHEA-AI

neutral

10/18/21 5:06 PM

NYSE : ZTS

management

Zoetis Announces Appointment of Robert J. Polzer, PhD, as President of Research & Development for World Leader in Animal Health

Zoetis Inc. today announced the appointment of Robert J. Polzer, PhD, as Executive Vice President and President of Research& Development for the company, effective Jan. 1, 2022. Polzer will become a member of the Zoetis Executive team and report to Chief Executive Officer Kristin Peck. Catherine Knupp, DVM, MS, and EVP and President of Research and Development at...

RHEA-AI

very positive

10/14/21 4:30 PM

NYSE : ZTS

dividends

Zoetis Declares Fourth Quarter 2021 Dividend

The Board of Directors of Zoetis Inc. has declared a fourth quarter 2021 dividend payable to holders of the company’ s common stock of $0.25 per share. The dividend is to be paid on Wednesday, December 1, 2021, to holders of record on Friday, October 29, 2021. In 2020, Zoetis generated revenue of $6.7 billion with~ 11,300 employees.

RHEA-AI

neutral

09/30/21 9:25 AM

NYSE : ZTS

conferencesearnings

Zoetis to Host Webcast and Conference Call on Third Quarter 2021 Financial Results

Zoetis Inc. will host a webcast and conference call at 8:30 a.m. on Thursday, Nov. 4, 2021. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review third quarter 2021 financial results and respond to questions from financial analysts during the call. In 2020, Zoetis generated revenue of $6.7...

RHEA-AI

neutral

ZTS Data:

IndustryPharmaceutical Preparation Manufacturing
Websitewww.zoetis.com
CeoKristin Peck
Security nameZoetis Inc - Class A
Issue typecs
SectorManufacturing
Sic code2834
Employees11300
Tags
- Health Technology
- Pharmaceuticals: Generic
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address10 Sylvan Way
StateNew Jersey
CityParsippany
Zip07054-3825
CountryUS
Phone19738227000

ZTS Description:

Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and precision livestock farming. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2019, the company generated annual revenue of $6.3 billion with approximately 10,600 employees.